Solutions To Clinical Trial Travel

Spurred by the COVID-19 pandemic, the life sciences industry has witnessed an increase in decentralized trial models and technology. While it could be easy to assume that patient travel has gotten easier or less frequent in recent years, an analysis of clinical trial participant travel described exactly the opposite: clinical trial travel rose from 29% in 2019 to 44% in 2021.¹

The report also found that trial participants in the analyzed group traveled, on average, 67 miles each way to visit trial sites and 60% had to travel more than 30 minutes one way. Furthermore, on average, rare disease participants traveled 135 miles for a study.

This increase in travel distance, time, and frequency suggests travel is a bigger barrier to patient recruitment and retention than the industry previously thought. Gain insight on how patient-centric approaches to clinical trial travel can increase participation and accelerate research.